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INTRODUCTION 
DIABETES 1: 
Diabetes mellitus represents a group of diseases of heterogenous etiology, 
characterised by chronic hyperglycemia, and other metabolic abnormalities, reporting from 
defects in insulin secretion, insulin action, or both .After a long duration of metabolic 
derangement specific complications of diabetes (retinopathy, nephropathy and neuropathy) 
may occur. Arteriosclerosis is also accelerated. Depending on the severity of the metabolic 
abnormality, diabetes may be asymptomatic or may be associated with symptoms like 
polyuria, polyphagia and polydipsia or may progress to ketoacidosis and coma. 
TYPES OF DIABETES 1&2: 
The etiological classification of diabetes and related disorders of glycaemia 
includes: 
 (1) Type 1 Diabetes   (2) Type 2 Diabetes (3) Those due to specific mechanisms and 
diseases and (4) Gestational diabetes. 
Type 1 diabetes (Insulin dependent diabetes): Type 1 is characterized by destructive 
lesions of pancreatic cells either by an autoimmune mechanism or of unknown cause. It 
can occur at any age, but it is most often diagnosed in children, teens, or young adults. In 
this disease, the body makes little or no insulin. Daily injections of insulin are needed.  
Type 2 diabetes (Non-Insulin dependent diabetes): Type 2 diabetes is characterized by 
combinations of decreased insulin secretion and decreased insulin sensitivity (insulin 
resistance) makes up most of diabetes cases. It most often occurs in adulthood, but teens 
and young adults are now being diagnosed with it because of high obesity rates.  
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Category (3) includes two subgroups; subgroup A is diabetes in which specific mutations 
have been identified as a cause of genetic susceptibility, while subgroup B is diabetes 
associated with other pathologic conditions or diseases 
Gestational diabetes is glucose intolerance developed/detected at any time during 
pregnancy.  
                 THE WHO report on diabetes issued in the month of August 2011 records that 3: 
1. More than 346 million people worldwide suffer from diabetes. 
2. There is an emerging global epidemic of diabetes that can be traced back to 
rapid increase in overweight, obesity and physical inactivity. 
3. Diabetes is predicted to become the seventh leading cause of death in the 
world by the year 2030. 
4. Total deaths from diabetes are projected to rise by more than 50% in the next 
10 years. 
5. Type 2 diabetes accounts for around 90% of all diabetes worldwide. Reports 
of type 2 diabetes in children-previously rare-have increased worldwide. 
6. In some countries, it accounts for almost half of newly diagnosed cases in 
children and adolescents. 
7. Eighty percent of diabetes deaths occur in developing and under developed 
countries. 
8. In developed countries most people with diabetes are above the age of 
retirement, whereas in developing countries those most frequently affected 
are aged between 35 and 64. 
9. Diabetes is a leading cause of blindness, amputation and kidney failure.  
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TYPE-2 DIABETES 4&5: 
Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of 
sugar (glucose) in the blood. Type 2 diabetes, often called non-insulin dependent diabetes, 
is the most common form of diabetes, affecting 90% - 95% of the 21 million people. 
The pathogenesis of type 2 diabetes is multifactorial and heterogeneous in origin, 
involving both genetic and environmental factors. It is characterized both by defects in 
insulin action (‘insulin resistance’) and in insulin secretion from the β-cells of the islets of 
langerhans. Insulin resistance initially can be compensated for by increased insulin 
production (hyperinsulinemia), but hyperglycaemia will develop when the β-cells can no 
longer meet the increased insulin requirement (‘β-cell failure’, ‘β-cell decompensation’ 
or‘β-cell exhaustion. This β-cell failure may be induced by a prolonged increase in insulin 
demand, and/or due to a genetic defect in β-cell function which is uncovered by insulin 
resistance. Other problems associated with the buildup of glucose in the blood include: 
• Dehydration The build up of sugar in the blood can cause an increase in urination. 
When the kidneys lose the glucose through the urine, a large amount of water is 
also lost, causing dehydration. 
• Diabetic Coma (Hyperosmolar nonketotic diabetic coma) When a person with 
type 2 diabetes becomes severely dehydrated and is not able to drink enough fluids 
to make up for the fluid losses, they may develop this life-threatening complication. 
• Damage to the body Over time, the high glucose levels in the blood may damage 
the nerves and small blood vessels of the eyes, kidneys, and heart and predispose a 
person to atherosclerosis (hardening) of the large arteries that can cause heart 
attack and stroke. 
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CAUSES6: 
1. Obese or overweight 
2. Women who have had gestational diabetes. 
3. People with family members suffering from diabetes 
4. People who have metabolic syndrome (a cluster of problems that 
include high cholesterol, high triglycerides, low good 'HDL' cholesterol and 
a high bad 'LDL' cholesterol, and high blood pressure). 
5. Inactive lifestyle. 
SYMPTOMS6: 
• Increased thirst. 
• Increased hunger (especially after eating). 
• Dry mouth. 
• Nausea and occasionally vomiting. 
• Frequent urination. 
• Fatigue (weak, tired feeling). 
• Blurred vision. 
• Numbness or tingling of the hands or feet. 
• Frequent infections of the skin, urinary tract or vagina. 
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DRUGS CURRENTLY USED IN THE TREATMENT OF DIABETES7: 
1) INSULIN: 
Insulin was the first medicine developed for the treatment of diabetes, and it 
remains the most effective therapy for treating hyperglycemia. Insulin reduces 
blood glucose levels by interacting with a protein on the surface of cells called 
the insulin receptor. 
2) ORAL HYPOGLYCEMICS: 
• Sulfonylurea: This family of medications includes gliclazide, glimepiride, and 
glyburide. These medications are widely recommended for type 2 diabetes and work by 
stimulating the pancreas to release insulin. However, these medications don't work for 
type 1 diabetes. 
• Biguanides: These medications include metformin and work to improve insulin 
sensitivity and to reduce the glucose produced by the liver. 
• Acarbose: This type of medication prolongs the absorption of carbohydrates after a 
meal. For these pills to work, they must be taken with or after a meal. 
• Thiazolidinediones: This family of medications includes pioglitazone and they 
work to improve insulin sensitivity. 
• Meglitinides: This family of medications includes repaglinide and nateglinide. 
They lower postprandial (after meals) glucose levels by stimulating the pancreas to 
release insulin. 
• Dipeptidyl peptidase-4 inhibitors: This class of medications includes sitagliptin 
and saxagliptin. They help improve insulin release from the pancreas and decrease liver 
release of glucose. 
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• GLP-1 analogs: This class of medications includes liraglutide, which is a synthetic 
form of the hormone GLP-1. It helps the body release insulin when blood sugar levels 
are high, and also reduces the release of sugar from the liver. It is taken as a daily 
injection under the skin. 
 The following table compares some common anti-diabetic agents, generalizing classes   
although there may be substantial variation in individual drugs of each class:  
Table 1a: Different Classes of Antidiabetic Drugs for Treatment of T2DM other than DPP-
IV        Inhibitors 
DRUG CLASS MOLECULAR 
TARGET 
SIT OF ACTION ADVERSE EFFECTS EXPECTED 
HbA1c 
REDUCTIO
N (%) 
 Insulin Insulin receptor Liver muscle Hypoglycemia, weight 
gain, edema 
1.5-2.5 
Sulfonylurea SU receptors Pancreatic Beta 
cells 
Hypoglycemia, weight 
gain 
1.5 
Biguanids Unknown Liver GI problems, lactic 
acidosis 
1.0-1.5 
 
Acarbose α-glucosidase Intestine GI problems 0.5-0.8 
Thiazolidinediones PPARᵟ Adipose tissue 
,liver, muscles 
Weight gain, edema, 
anaemia 
0.5-1.4 
PPARα/ᵟ dual 
agonists 
PPAR α/ᵟ Adipose tissue, 
liver, muscles 
Edema ,hepatotoxicity, 
cardiac risk 
0.5-1.3 
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INCRETIN THERAPIES8&9: 
Incretins are a group of gastrointestinal hormones that cause an increase in the 
amount of insulin released from the beta cells of the islets of Langerhans after eating, even 
before blood glucose levels become elevated. They also slow the rate of absorption of 
nutrients into the blood stream by reducing gastric emptying and may directly reduce food 
intake. As expected, they also inhibit glucagon release from the alpha cells of the Islets of 
Langerhans. Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl 
peptidase-4 (DPP-4). 
There are two main incretin hormones in humans, GIP (glucose-dependent 
insulinotropic peptide; also known as gastric inhibitory peptide) and GLP-1 (glucagon-like 
peptide-1). Both hormones are secreted by endocrine cells that are located in the 
epithelium of the small intestine. 
There has been a lot of interest in developing incretin-based therapies for the 
treatment of type 2 diabetes mellitus (T2DM). T2DM is characterized by insulin resistance, 
which is a decreased responsiveness of tissues to insulin, and so it may lead to a relative 
insulin deficiency.  
DISADVANTAGES OF GLP-110: 
GLP-1 (7-36) amide is not very useful for treatment of type 2 diabetes mellitus, 
since it must be administered by continuous subcutaneous infusion. Several long-lasting 
analogs having insulinotropic activity have been developed, and two, exenatide (Byetta) 
and liraglutide (Victoza), have been approved for use in the U.S. The main disadvantage of 
these GLP-1 analogs is they must be administered by subcutaneous injection. 
8 
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 Another approach is to inhibit the enzyme that inactivates GLP-1 and GIP, DPP-4. 
Several DPP-4 inhibitors that can be taken orally as a tablet have been developed. One of 
them, Januvia (sitagliptin) was approved by the FDA on October 18, 2006. 
DPP-4 INHIBITORS10: 
DPP-IV is a serine aminopeptidase that inactivates incretins, especially GLP-1 and 
GIP, which are gut hormones released in response to food intake. GLP-1 has several 
glucoregulatory activities. As soon as it is released from the gut during meals, the incretin 
hormones (GLP-1 and GIP) serve as enhancers of glucose-dependent insulin release from 
pancreatic β-cells .As GLP-1 is rapidly eliminated (within 1 minute) because of its 
cleavage by DPP-IV into an active metabolite, several strategies were explored including 
the exogenous GLP-1, GLP-1 fusion proteins and DPP-IV resistant GLP-1 analogs for the 
treatment of Chronic infusion of GLP-1 to T2DM patients resulted in a significant decrease 
in both blood glucose and plasma HbA[1c] levels. However, the requirement of parenteral 
route of administration and potential for development of auto antibodies are the major 
drawbacks associated with this therapeutic approach. In addition sustained GLP-1 infusion 
induced nausea and vomiting in clinical studies. Thus, DPP-IV has emerged as a potential 
therapeutic target for the treatment of T2DM.  
MECHANISM OF ACTION10: 
  The mechanism of action by which DPP-IV inhibitors lower blood glucose is 
distinct from existing class of oral glucose-lowering agents. They control elevated blood 
glucose by potentiating pancreatic insulin secretion, increasing circulating GLP-1, 
reducing glucagon secretion, and signalling the liver to reduce glucose production. 
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DPP-IV ENZYME: STRUCTURE, CATALYSIS REQUIREMENTS AND 
SUBSTRATE SPECIFICITY10: 
DPP-IV is a 766 amino acid long amino peptidase. The crystal structure of DPP-IV 
revealed that it is a tetramer with each subunit comprising of two structural domains, N- 
terminal β propeller domain and C-terminal catalytic domain. The β propeller domain 
consists of eight blades with 4 anti-parallel strands and harbors an ellipsoidal and 
continuously open tunnel. The catalytic domain adopts a typical α/β hydrolase fold with a 
central eight stranded β sheet sandwiched by several α helices. The active site of the 
enzyme is covered by the β-propeller domain thus restricting access to the substrate. 
Therefore, there are two possible routes for substrate access: tunnel through the β propeller 
domain enter by or a side opening formed at the interface of β-propeller domain and 
catalytic domain. 
DPP-IV is a glycosylated protease belonging to the subset of proteins that are 
capable of cleaving post-proline bond two amino acids downstream of the N-terminal of 
the protein. It has preference for X-Proline over X-Alanine, where X is any amino acid 
other than proline. It is generally believed that glycolysation of an integral protein is 
required for its enzymatic activity.  
  Based on the in vitro studies, a wide range of potential substrates including growth 
hormone-releasing hormone, bradykinin, certain chemokines, neuropeptide Y, exenatide 
have been identified but only few of them such as GLP-1 and GIP are reported to be the 
endogenous substrates. Although DPPIV has a preference for proline in the second 
position but GLP-1, the endogenous substrate of DPP-IV, has alanine in this position. A 
high expression of this enzyme is observed in kidneys, where it is localized in the 
glomerular basement membrane and proximal convoluted tubules.  
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PHYSIOLOGICAL ACTIONS OF INCRETIN HORMONES, THEIR USE AND 
LIMITATIONS10: 
In the recent years, approaches targeting elevation of GLP-1 have emerged as a 
promising area for T2DM therapy. They stimulate glucose dependent insulin secretion, 
inhibit glucagon secretion, delay gastric emptying, suppress appetite, stimulate 
differentiation and proliferation and inhibit apoptosis of  β-cells thus they increase the β-
cell mass and improve peripheral glucose uptake and disposal. Extra pancreatic actions 
include the reduction of hepatic insulin clearance and an apparent “insulin mimetic” effect 
on skeletal muscle, liver and adipose tissue. But the half life of these hormones is very 
short (t1/2 =~1 min) as they are rapidly cleaved by circulating DPP-IV enzyme to produce 
an inactive product, GLP-1 (9-36aa) amide. Inhibition of circulating DPP-IV enzyme by 
DPP-IV inhibitors prolongs the half life of GLP-1 leading to increased levels of active 
endogenous GLP-1 and GIP.  
SELECTIVITY ISSUES OF DPP-IV INHIBITORS10: 
DPP-IV is a member of a family of serine peptidases that includes other related 
members like quiescent cell prolinedipeptidase (QPP/DPP2), DPP6, DPP8, DPP9 and 
DPP10. The catalytic regions of these enzymes show similarity to each other and therefore 
a DPP-IV inhibitor may also inhibit the related enzymes in body to a certain extent. For 
example, the DPP-IV inhibitor Val-boro-pro appears to be relatively nonselective for DPP-
IV as it may also inhibit FAP, DPP8, DPP9 and DPP2. Functions of other family members 
and their clinical importance are unclear at present. Lankaset. al. [113] found that 
administration of DPP8/9 inhibitor produced alopecia, thrombocytopenia, reticulocytpenia, 
enlarged spleen, multiorgan histopathological changes and mortality in rats and GI 
toxicities in dogs.  
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QPP inhibitor was found to produce reticulo cytopenia in rats, but selective DPP-IV 
inhibitor exhibited no toxicities in these species. Moreover DPP8/9 inhibitor attenuated T-
cell activation in human in vitro models. Based on the above preclinical study data, it was 
perceived that selective inhibitors of DPP-IV may be a safe clinical candidate for T2DM. 
The degree of selectivity towards DPP-IV inhibition for a compound to become 
pharmacologically safe drug is estimated and summarized below: 
Table 1.b Potency of DPP-IV Inhibitors Against Closely Associated Enzymes 
      Compound                                   IC 50 (nM) 
 DPPIV DPP8 DPP9 DPP2 FAP 
Sitaglipitin 18 48000 >10,000 >100000 >100000 
Vildaglipitin 3.5(Ki=3) Ki=810 Ki=95 >500000 NA 
BI1356 (Ondero) 1.0 >40000 >10000 >100000 89 
Aloglipitn 7.0 >100000 >100000 >100000 >100000 
Saxaglipitn 3.37 244 104 >30000 NA 
Meloglipitn(GRC 8200) 1.61 NA NA NA NA 
 
CURRENT OPINION ON DPP-IV INHIBITORS VS GLP-1 ANALOGS10: 
Both DPP-IV and GLP-1 based therapeutic approaches have been approved by 
FDA for T2DM. Current evidience suggests that both DPP-IV and GLP-1 analogs may 
exhibit beneficial actions on the pancreatic islets, acting to preserve β-cell mass via 
opposing effects on proliferation and apoptosis. However , DPP-IV inhibitors are small, 
orally bio available low-molecular weight compounds but they are without any inherent 
anti-diabetic activity of their own and hence their therapeutic effect is reliant on enhancing 
12 
Department of Pharmaceutical Chemistry 
the activity of GLP-1 and GIP whereas all GLP-1  analogs are based on naturally 
occurring, relatively large peptide with inherent anti-diabetic activity. Currently there are 
no small-molecule GLP-1 mimetic drugs available for oral administration and thus they 
must be given parenterally. Researchers in many industries and academic labs are working 
on development of oral small molecule agonists of GLP-1 receptor to overcome the 
existing limitation (injectable and less stable) of GLP-1 based therapy. Although GLP-1 
based therapy offers physiological benefits, but it is also associated with adverse events 
like hypoglycaemia, nausea etc as observed in human clinical trials. Further, modified 
GLP-1 peptide based analogs are potentially immunogenic. However, none of the 
compounds under investigation were reported to elicit any antibody response and thus the 
potential side effects of GLP-1 mimetics need to be evaluated further in long term studies. 
The anti hyperglycaemic effects of DPP  IV inhibitors is glucose dependent meaning that 
the stimulation of insulin release by these compounds depends upon elevated ambient 
blood glucose levels and hence there may not be a potential risk of hypoglycaemia. 
However, long-acting DPP-IV resistant GLP-1 analogs may cause hypoglycaemia and thus 
dose regimen to be administered should be monitored carefully. Although both GLP-1 and 
DPP-IV inhibitor based therapies have been approved to be clinically efficacious as 
monotherapy but DPP-IV combination therapy (with TZD’s, SU or biguanides) may be a 
safer therapeutic approach. GLP-1 analog based therapy causes reduction in body weight, 
which has not been observed in DPP-IV inhibition based therapy. Considering all the 
above effects, DPP-IV inhibitor possess more advantages (orally bioavailable, small 
molecular weight, low hypoglycaemic risk, weight neutral etc)over GLP-1 analogs, but the 
long-term effects of DPP-IV inhibitors in T2DM patients need to be explored because of 
its role in regulation of other physiological hormones, chemokines and many other 
substrates. 
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THE DRUG DISCOVERY PROCESS12: 
Drug discovery is the mission of pharmaceutical research to take the path from 
understanding the disease to bring a safe and effective new treatment to patients. Drug 
discovery and development is an intense, lengthy and an interdisciplinary endeavour. Drug 
discovery is mostly portrayed as a linear, consecutive process that starts with target and 
lead discovery, followed by lead optimization and pre-clinical in vitro and in vivo studies 
to determine if such compounds satisfy a number of pre-set criteria for initiating clinical 
development. The multiple stages of drug discovery process are: 
 
 
 
 
 
 
TARGET IDENTIFICATION AND VALIDATION: 
Target identification involves choosing a molecule to target with the drug. A target 
is generally a single molecule, such as gene or protein, which is involved in a particular 
disease. The target should be selected in such a way that it could potentially interact with 
and be affected by the drug molecule. 
 
 
TARGET 
VALIDATION 
 
SCREENING & 
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CLINICAL 
TRIALS 
 
DEVELOPMENT 
 
LEAD 
OPTIMIZATION 
 
ASSAY 
DEVELOPMENT 
 
TARGET 
DISCOVERY
14 
Department of Pharmaceutical Chemistry 
LEAD IDENTIFICATION: 
Lead identification is the search for the molecule or lead compound that may act on 
the target to alter the disease course. The ways to find a lead compound are as follows: 
De novo: 
De novo design refers to a computer assisted molecular design that supports drug 
discovery by suggesting novel chemotypes and compound modifications for lead structure 
optimization. 
High-throughput Screening:  
  This process is the most common way that leads are usually found. Advances in 
robotics and computational power allow researchers to test hundreds of thousands of 
compounds against the target to identify any that might be promising. Based on the results, 
several lead compounds are usually selected for further study. 
Biotechnology:  
This field involves genetically engineering living systems to produce disease-
fighting biological molecules. 
LEAD OPTIMIZATION: 
Lead compounds that survive the initial screening are then “optimized,” or altered 
to make them more effective and safer. By changing the structure of a compound, its 
properties could be altered. For example, they can make it less likely to interact with other 
chemical pathways in the body, thus reducing the potential for side effects. Hundreds of 
different variations or “analogues” of the initial leads are made and tested. Teams of 
15 
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biologists and chemists work together closely: The biologists test the effects of analogues 
on biological systems while the chemists take this information to make additional 
alterations that are then retested by the biologists. The resulting compound is the candidate 
drug. 
New techniques such as magnetic resonance imaging, X-ray crystallography, along 
with powerful computer modelling techniques helps us to visualise the target in three 
dimensions and design potential drugs to more powerfully bind to the parts of the target 
where they can be most effective. 
DRUG DESIGN 13: 
For the pharmaceutical industry, the number of years to bring a drug from 
discovery to market is approximately 12-14 years and costing up to $1.2 - $1.4 billion 
dollars. Traditionally, drugs were discovered by synthesizing compounds in a time-
consuming multi-step processes against a battery of in vivo biological screens and further 
investigating the promising candidates for their pharmacokinetic properties, metabolism 
and potential toxicity. Such a development process has resulted in high attrition rates with 
failures attributed to poor pharmacokinetics (39%), lack of efficacy (30%), animal toxicity 
(11%), adverse effects in humans (10%) and various commercial and miscellaneous 
factors. Today, the process of drug discovery has been revolutionized with the advent of 
genomics, proteomics, bioinformatics and efficient technologies like, combinatorial 
chemistry, high throughput screening (HTS), virtual screening, de novo design, in vitro, in 
silico ADMET screening and structure-based drug design. 
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There are two major types of drug design.  
                    1.  LIGAND BASED DRUG DESIGN 
                    2. STRUCTURE BASED DRUG DESIGN 
 
IN-SILICO DRUG DESIGN: 
In-silico methods can help in identifying drug targets via bioinformatic tools. They 
can also be used to analyse the target structures for possible binding/active sites, generate 
candidate molecules, check for drug likeness, dock these molecules with the target, rank 
them according to their binding affinities, further optimise the molecules to improve 
binding characteristics. 
The use of computers and computational methods permeates all aspects of drug 
discovery today and forms the core of structure-based drug design. High Performance 
computing, data management software and internet are facilitating the access of huge 
amount of data generated and transforming the massive complex biological data into a 
workable knowledge in modern day drug discovery process. The use of complementary, 
experimental and informatics techniques increases the chance of success in many stages of 
drug discovery process, from the identification of novel targets and elucidation of their 
functions to the discovery and development of lead compounds with desired properties. 
Computational tools offer the advantage of delivering new drug candidates more quickly 
and at lower cost. Major roles of computation in drug discovery are; 
1. Virtual screening and de novo design 
2. Insilico ADME/T production 
3. Advanced methods for determining protein ligand binding 
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LIGAND-BASED RUG DESIGN: 
Ligand based approaches commonly consider two or three dimensional chemistry, 
shape, electrostatic and interaction points (e.g. Pharmacophore modelling) to assess 
similarity.  
STRUCTURE BASED DRUG DESIGN (SBDD) 13: 
Structure based design attempts to use the three dimensional (3D) protein structure to 
predict which ligands will bind to the target. Structure-based approaches, of which the best 
known is docking, require a protein structure or homology model as a starting point. SBDD 
is an iterative process, in which macromolecular crystallography has been the predominant 
technique used to elucidate the 3D of drug targets. Although both nucleic acids and 
proteins are potential drug targets, by far the majority of such targets are proteins. Given 
that many proteins undergo considerable conformational change upon ligand binding, it is 
important to design drugs based on the crystallographic structures of protein-ligand 
complexes. 
Crystallography has been successfully used in the de novo design of drugs, but its most 
important use has been, and will continue to be, in lead optimization .It is important to note 
that what is being optimized is the affinity and specificity of compounds to their drug 
target.  
Lead optimization is a multi-step process that can be summarized as follow: 
1. Expression and purification of the protein of interest. Crystallisation of the 
protein in the presence of a ligand, which can be a non-hydrolysable substrate or 
can come from a biochemical or a cell-based screen. 
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2. Ligands can be low affinity compound fragments or scaffold. They are generally 
a collection of basic chemical building blocks, each with a molecular weight of 
less than 200 Daltons. If the screen identifies several promising ligands, each 
with a unique scaffold, determine the structures of the drug target with as many 
of these as possible. 
3. One or more ligands have been determined and refined, analysis of each 
structure will reveal sites on the ligand that can be optimized to enhance potency 
to the drug target. This can be accomplished by redesigning the ligand with 
greater hydrophobic, hydrogen-bonding and electrostatic complementary to the 
molecular target. A high affinity lead makes the drug design process simple and 
intuitive. 
4. After the ligands have been designed they should be chemically synthesized. It 
is prudent to synthesise five to ten compounds around the proposed ligand to 
obtain structure-activity relationship (SAR) data. 
5. Once the synthesised compounds are purified, they are tested in a relevant 
biochemical or cell-based assay to determine whether or not the design was 
successful. 
PRE-CLINICAL TESTING: 
In-vitro and In-vivo tests are carried out before the candidate drug could be 
administered in humans. In vitro tests are experiments conducted in the lab, usually carried 
out in test tubes and beakers and in vivo studies are those in living cell cultures and animal 
models. 
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CLINICAL TRIAL DESIGN: 
An incredible amount of thought goes into the design of each clinical trial. To 
provide the highest level of confidence in the validity of results, many drug trials are 
placebo controlled, randomized and double-blinded. 
• Placebo-controlled: Some subjects will receive the new drug candidate and others will 
receive a placebo. (In some instances, the drug candidate may be tested against another 
treatment rather than a placebo.) 
• Randomized: Each of the study subjects in the trial is assigned randomly to one of the 
treatments. 
• Double-blinded: Neither the researchers nor the subjects know which treatment is being 
delivered until the study is over. This method of testing provides the best evidence of any 
direct relationship between the test compound and its effect on disease because it 
minimizes human error. 
THE DEVELOPMENT PROCESS: 
INVESTIGATIONAL NEW DRUG (IND) APPLICATION AND SAFETY: 
Before any clinical trial can begin, the researchers must file an Investigational New 
Drug (IND) application with the FDA. The application includes the results of the 
preclinical work, the candidate drug’s chemical structure and how it is thought to work in 
the body, a listing of any side effects and manufacturing information. The IND also 
provides a detailed clinical trial plan that outlines how, where and by whom the studies 
will be performed. 
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The FDA reviews the application to make sure people participating in the clinical 
trials will not be exposed to unreasonable risks. 
In addition to the IND application, all clinical trials must be reviewed and approved 
by the Institutional Review Board (IRB) at the institutions where the trials will take place. 
This process includes the development of appropriate informed consent, which will be 
required of all clinical trial participants. 
CLINICAL TRIALS: 
PHASE: 1 
In this phase the drug is tested on 20 to 100 healthy volunteers. The main goal of this phase 
is to discover if the drug is safe with humans. The pharmacokinetics of the drug are 
analysed and the safe dosing range is determined and moved on to the next stage of 
development. 
PHASE: 2 
In Phase 2 trials the candidate drug’s effectiveness is evaluated in about 100 to 500 
patients with the disease or condition under study, and examine the possible short-term 
side effects (adverse events) and risks associated with the drug. If the drug seems to be 
promising in this stage it is been taken to the next level. 
PHASE: 3 
In Phase 3 trials researchers study the drug candidate in a larger number (about 
1,000-5,000) of patients to generate statistically significant data about safety, efficacy and 
the overall benefit-risk relationship of the drug. This phase of research is key in 
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determining whether the drug is safe and effective. It also provides the basis for labelling 
instructions to help ensure proper use of the drug. 
ONGOING STUDIES AND PHASE 4 TRIALS: 
Research on a new medicine continues even after approval. As a much larger 
number of patients begin to use the drug, companies must continue to monitor it carefully 
and submit periodic reports, including cases of adverse effects to FDA. 
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REVIEW OF LITERATURE: 
Review of literature was carried out on the basis of the categories docking, 
synthesis and anti-diabetic activity. In this study high docking scores were obtained for the 
purine nucleus and hence the literature survey was also proceeded. 
DRUG DESIGN: 
Nam Sook Kang., et al14., (2007) described the docking-based 3D- QSAR study for 
selectivity of DPP4, DPP8 and DPP-9 inhibitors. 
Ying- Duo Goa., et al.15,(2007) revealed a novel, potent, and selective 
pyrrolopyrimidine DPP-4 inhibitors by modeling assisted rational design . 
    Jennifer E.Kowalchick., et al.16,(2007) described the design, Synthesis, and biological 
evaluation of triazolopiperazine-based-β-amino amides as potent, orally active dipeptidyl 
peptidase(IV) inhbitors. 
J.W.Corbett., et al.17,(2007) explained the design and synthesis of potent amido- 
and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. 
Bradley J. Backes., et al.18, (2007) done a job with Pyrrolidine-constrained 
phenethylamines: The design of potent, selective, and pharmacologically efficacious 
dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit. 
Takashi Kondo., et al.19,(2008) explained design and synthesis of DPP-IV 
inhibitors lacking the electrophilic nitrile group. 
Mutasem.O.Taha., et al.20,(2008) revealed the Discovery of DPP IV Inhibitors by 
Pharmacophore Modeling and QSAR Analysis followed by in silico Screening 
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U.Saquib., et al.21, (2009) using 3-D QSAR carried out studies on 
triazolopiperazine amide inhibitors of dipeptidyl peptidase IV as anti-diabetic agents.  
Atulkumar et.al. 22, Design and Synthesis of 3,5-diaryl isoxazole derivatives as 
novel class of anti-hyperglycemic and lipid lowering agents”. Bioorganic and Medicinal 
Chemistry 17 (2009) pg.no: 5285-5292 
Huang Jae Kim., et al.23, (2011) explains the discovery of DA-1229: A potent, long 
acting dipeptidyl peptidase-4 inhibitor for the treatment of type-2 diabetes. 
 
SYNTHESIS: 
Young-Tae Chang.,et.al.24,(1999) described the Synthesis and application of 
functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. 
Win-Long Chia.,et.al.25,(2001) explained the novel synthesis of liquid crystalline 
compounds of 5-substituted 2-(4-alkylphenyl)pyridines. 
 
 
Morten Brændvang.,et.al.26,(2005) synthesised  Selective anti-tubercular purines 
and explained chemotherapeutic properties of 6-aryl- and 6-heteroaryl-9-benzylpurines. 
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Fernanda Gambogi Braga.,et.al.27,(2007) explained the Synthesis and biological 
evaluation of some 6-substituted purines  
                                                
Ana Conejo-García.,et.al.28,(2008) described the regiospecific microwave-assisted 
synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- 
or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or 9H-purines  
                                      
 
Stephen O. Ojwach; et.al.29, (2009) (Pyrazol-1-ylmethyl) pyridine palladium 
complexes: Synthesis, molecular structures, and activation of small molecules 
Pedro Besada; et.al.30,( 2010) explained the synthesis and cytostatic activity of 
purine nucleosides derivatives of allo furanose 
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P. Sadanandam., et.al.31, (2011) synthesised and characterization of 9-methyl-2-
morpholin-4-yl-8-substituted phenyl-1H-purine derivatives using polyphosphoric acid 
(PPA) as an efficient catalyst. 
Viktor O. Iaroshenko.,et.al.32,(2011) described the efficient synthesis of purines by 
inverse electron-demand Diels–Alder reactions of 1-substituted-1H-imidazol-5-amines 
with 1,3,5-triazines 
                            
Abdalla E.A. Hassan., et.al.33, (2012) synthesised and evaluated the substrate activity of 
C-6 substituted purine ribosides with E. Coli purine nucleoside phosphorylase: Palladium 
mediated cross-coupling of organo zinc halides with 6-chloropurine nucleosides 
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ANTI-DIABETIC ACTIVITY: 
Vincent Marks et.al.34,(1959) An improved glucose-oxidase method for 
determining blood C.S.F and urine glucose level. 
Vincent Marks et.al.35, (1965) Rapid Stick Method for determining Blood glucose 
concentration  
J.S.Cheanet.al.36, (1974)  A Rapid and Simple blood sugar determination using the 
Ames Reflectance meter And Dextrostix system. A Preliminary Report. 
Debro.T.Bustick et.al.37,(1975)Quantitative determination of blood glucose using 
enzyme induced chemiluminescence of luminol. 
V.T. Innanen., et.al.38,(1991) Hypoglycemia is effectively evaluated at the bedside 
by the ames glucometer 
Ulf Hannestad et.al.39, (1997) Accurate and precise isotopic dilution mass 
spectrometry method for determining glucose in whole blood. 
Vincenzo Calderone., et.al.40, (2009) NO-glibenclamide derivatives: Prototypes of 
a new class of nitric oxide-releasing anti-diabetic drugs. 
 
27 
Department of Pharmaceutical Chemistry 
AIM AND OBJECTIVES: 
AIM: 
 To develop novel, potent, selective and orally active inhibitors of Dipeptidyl Peptidase IV 
with Anti-Diabetic activity. 
OBJECTIVES: 
1. Identification of common Pharmacophore features responsible for inhibiting DPP-IV 
using Hiphop module of Catalyst® software 4.11 from Accelrys. 
2. Devlopment and validation of quantitative Pharmacophore hypothesis for series of 
DPP-IV receptor using Hypogen/Hyporefine module of Catalyst® software 4.11 from 
Accelrys. 
3. Generation of 10,000 scaffolds from the drug using scaffold hopping technique. 
4. Prediction of activity for designed molecules using the Hyporefine model and to 
identify novel and potent DPP IV receptor using Lipinski rule of five. 
5. The potent receptor inhibitors attained as results may be used as lead for drug 
development. 
6. From the lead molecule, the derivatives of the compounds which has higher score value 
were synthesised. 
7. Characterization of the synthesized compounds by UV, Infrared spectroscopy, Nuclear 
Magnetic Resonance spectroscopy and Mass Spectroscopy. 
8. In vivo anti diabetic activity of synthesised compounds. 
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The present study was conducted according to the following design 
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     GLIDE 
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DRUG DESIGN 
CHEMICAL AND 
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PRIORITAZTION BASED ON 
THE CASE OF SYNTHETIC 
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4.1 MATERIALS AND METHODS:                                          
4.1 DRUG DESIGN: 
  Drug design is the process in which drugs are designed at the atomic level to 
interact with targets associated with a particular disease process. The designing process is 
based on the knowledge of the biological target. Here two softwares were used namely 
Catalyst ® and Glide®. Catalyst ® for Pharmacophore modelling and Glide® for docking 
studies. 
PHARMACOPHORE STUDIES41: (Catalyst ®) 
 A Pharmacophore is a representation of generalized molecular features including 
three dimensional structures (3D) (hydrophobic groups, charged/ionisable groups, 
hydrogen bond donors/acceptors), two dimensional (2D) (substructures), and one 
dimensional (1D) (physical or biological) properties that are considered to be responsible 
for a desired biological activity.  
Catalyst ® develops 3D models called hypotheses from a collection of molecules 
possessing a range of diversity in both structures and activities. These hypotheses could be 
used as queries to search 3D databases to retrieve structures that fit the hypothesis, or as 
models to predict the activities of novel compounds. Catalyst ® specifies hypotheses in 
terms of chemical features that are likely to be important for binding to the active site.  
Cerius2 42:  
Cerius2 is a part of Catalyst ® .Cerius2 has a variety of force fields available. The 
default force field is the universal force field (UFF). Cerius2 offers abilities for modelling 
materials structure properties, and processes with applications in catalysis, crystallisation 
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and polymer science.Cerius2 is a suite of molecular modelling and simulation package for 
smaller molecules. 
CATALYST ®: 
4.1.1 PHARMACOPHORE MODEL GENERATION41:  
         Catalyst ® attempts to compute a model from training set data that correlates 
estimated activities with measured activities. The model is a collection of chemical 
features distributed in 3D space that is intended to represent groups in a molecule that 
participate in important binding interactions between drugs and their receptors. Estimated 
activities are computed by comparing how well the chemical features in the 
model(hypothesis).The proficiency of molecules to adjust their conformations in order to 
fit a receptor better is accommodated by considering the molecule as collection of 
energetically reasonable conformations(conformation models) during the analysis. The 
steps involved in Pharmacophore model generation are given below: 
DEVELOPING A 3D QSAR PHARMACOPHORE MODEL IN CATALYST ® 41: 
                     The objective here is to develop an automated method for selecting a training 
set that can be used for Catalyst ® hypothesis generation from a large collection 
of compounds. Training set selection from a given SAR data is the first step in 
deriving a predictive QSAR model. The quality of the resultant model is highly 
dependent upon the molecules which are used to derive the model; therefore, 
selection of these compounds must be done very carefully. 
Guidelines for 3D QSAR Model Generation in Catalyst ® 41: 
3D QSAR (HypoGen) model generation within Catalyst ® requires the following 
guidelines in order to select molecules for hypothesis generation: 
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1. At least 16 compounds to assure statistical significance of the Pharmacophore 
model 
2. Activity range of the compounds should span at least 4 orders of magnitude 
3. Each order of magnitude should be represented by at least three compounds 
4. The most active and inactive compounds should be included 
5. Two compounds with similar structures m u s t  d i f f e r  i n  a c t i v i t y  b y  
magnitude to be included, otherwise the most active of the two must be taken. 
6. Two compounds with similar activities must be structurally distinct in 
order to be included, otherwise the most active of the two must be taken. 
7. No redundant information should be included 
3D fingerprint for a compound is defined as the collection of all possible combinations of 
three features or four features fingerprints in three dimensions f o r  a l l  c o n fo rm e rs .  
Each multiplet is characterised by a set of feature types and the corresponding inter-feature 
distances. 
.        Shape descriptors are calculated for all multi-conformer compounds using the 
Catalyst® functionality “Catshape”. The shape descriptors consists of volume descriptors 
(mean, median) and x, y and z components of principal axes (min,max,mean,range and 
median). 
     A principle component analysis is then performed on the descriptors (MDS coordinates 
derived from 3D fingerprint, shape and activity) to reduce the high dimensionality 
descriptor data into principle components. To visualize the compounds in three 
dimensions, the first three principle components are plotted. The last step is to select a 
diverse set of compounds to be used a training set for developing hypogen module in 
Catalyst ®. 
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HYPOGEN-GENERATE HYPOTHESIS42: 
With the input of full range of training set compounds from inactive to active, the 
hypogen algorithm can generate hypothesis with features common against active molecules 
and missing from inactive molecules 
 Hypothesis is generated in three main steps: 
1: Constructive Phase 
2. Substractive Phase 
3. Optimization Phase 
 
CONSTRUCTIVE PHASE: 
Hypothesis common against the active compounds are identified in the constructive 
step. These compounds are determined by performing a simple calculation based on the 
activity and uncertainty as a matter of fact the activity of most active compound is 
multiplied by the uncertainty ( which is set equal to 3 by default in the software) to the 
uncertainty and this result in,”B” which is compared to A. If B is smaller than A then the 
compound is included in the most active set, if not the procedure stops. 
For the identification of Actives: 
(Most Active Compound* Uncertainty) – (CompoundX/ Uncertainity) >0 
  In the constructive step the actives must fit at least the minimum features. 
SUBTRACTIVE STEP: 
The inactive compounds are identified in this phase using  
Log (Compound X)-log (Most Active compound)>3.5 
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If more than half doesn’t fit with pharmacophoric features, the inactives are identified and 
removed. 
OPTIMIZATION STEP: 
SIMULATED ANNEALING: 
   The optimization of quantitative Pharmacophoric models were done by simulated 
annealing. The best score hypothesis were estimated for its quality and complexity and the 
top 10 were selected. 
HYPOREFINE: 
This process permits consideration of exclusion volumes in Pharmacophore-baed 
3D QSAR optimization. The result is to obtain better model predictivity where biological 
activity is determined by considerations of molecular shape. 
EXCLUSION VOLUME 
An excluded volume can be added to a hypothesis(or to a template molecule) to 
specify one or more spherical spaces that must not contain any atoms or bonds.An 
exclusion volume can represent a region in space that might impinge sterically on a 
receptor .An exclusion volume can be interpreted as a geometrical constraint. 
 COMPARE/FIT: 
This provides the ability to fit compounds and hypotheses, and determine their 
degrees of similarity, both geometrically and functionally. In a database search, 
COMPARE fits the original hypothesis onto the hit molecules obtained from the search 
and a score are calculated according to the geometrical fit. 
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DATA ANALYSIS: 
COST ANALYSIS: 
                        The Hypogen module in the Catalyst ® performs two important theoretical 
cost calculations (represented in bit units) that determine the success of any 
Pharmacophore hypothesis. 
FIXED COST: 
Fixed cost (also termed as ideal cost) represents the simplest model that fits all data 
perfectly 
NULL COST: 
Null cost (also termed as the no correlation cost) which represents the highest cost 
of a Pharmacophore with no features and estimates activity to be the average of the activity 
data of the training set molecules. 
   A meaningful Pharmacophore hypothesis may result when the difference between 
the null cost and the fixed cost is large. The total cost (Pharmacophore cost) of the 
Pharmacophore hypothesis should be close to fixed cost to provide any useful data’s. 
  The other parameters determining the quality of the Pharmacophore hypothesis are 
the configuration cost or the entropy cost which should be <17 and the error cost which is 
dependent on the root mean square differences between the estimated and the actual 
activities of the training set molecules. The Root Mean Square Deviation (RMSD) 
represents the quality of the correlation between the estimated and the actual activity data. 
The best Pharmacophore model has the highest cost difference, lowest RMSD and best 
correlation coefficient 
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                        Pharmacophore were computed and the top-10 hypotheses were exported. 
Results of Pharmacophore hypotheses are presented in Table-5a.  Top 10 hypotheses were 
output by Catalyst ® with cost values, RMSD and Pharmacophore features as listed in the 
table 5a. The top ranked one, OutHypo-1 consists of two hydrophobic Aliphatic and one 
Positive ionisable features. The quality of the generated Pharmacophore hypotheses was 
evaluated by considering the cost functions calculated by Hypogen module during 
hypotheses generation. In detail, the null cost and fixed cost of the 10 top scored 
hypotheses were equal to 147.217 and 94.635 and the configuration cost was 
12.784.Hypo1 is the best Pharmacophore hypotheses in this study, as it is characterized by 
the lowest total cost(116.3),the highest cost difference between the null and total 
hypotheses cost(52.582),the lowest RMSD(1.34256) and the best correlation 
coefficient(0.821441).The values of the Hypo1 could indicate high predictability of the 
quantitative Pharmacophore model and a certain rationality for further analysis 
Pharmacophore model. 
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             5(a)    Pharmacophore model aligned with the most inactive molecule 
 
             5(b)        Pharmacophore model aligned with the most active molecule 
5(c) Phrmacophore model for DPP-4 inhibitor with its distance constraints   
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 Training set 24 molecules contains low, moderate and highly active molecules with IC50 
values 
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38 
Department of Pharmaceutical Chemistry 
                        Table: 5a Results of Pharmacophore hypothesis generated using training set against DPP-IV    inhibitors 
HYPO. NO TOTAL COST  COST DIFFERENCE RMSD Corr. FEATURE     MAX.FIT 
1. 116.3 21.665 1.34256 0.821441 HBA HBA HYA HYA PI 10.3979 
2. 124.539 29.904 1.57805 0.742033 HBA HYA HYA PI  8.23945 
3. 126.11 31.475 1.61807 0.72638 HBA HBA HYA PI  8.40509 
4. 128.464 33.829 1.65385 0.712549 HBA HYA HYA PI RA 7.8591 
5. 128.48 33.845 1.67482 0.702937 HBD HYA HYA PI  7.26669 
6. 128.658 34.023 1.68091 0.700307 HBA HBA HYA PI  8.58388 
7.                                                                                     128.805 34.17 1.66784 0.706499 HBA HYA HYA PI RA 8.10273 
8. 129.119 34.484 1.68114 0.70153 HBA HYA PI RA  9.28727 
9. 129.4 34.675 1.69018 0.696601 HBD HYA HYA RA  6.81174 
10. 129.669 35.034 1.70863 0.687834 HBA HBA HY PI  7.95771 
*Null cost ; Fixed cost; Configuration cost-12.784.All cost units are in bits. *HBA - Hydrogen Bond Acceptor, HYA- Hydrophobic Aliphatic,  
PI-Positive ionisable, RA-Ring Aromatic 
39 
Department of Pharmaceutical Chemistry 
Table: 5b Experimental and predicted IC50 values for 24 training set molecules along with 
other details such as error values and fitness scores. 
COMP
OUND 
NO 
IC50 ERROR 
VALUE 
FIT 
VALUE 
ACTIVITY 
SCALE 
MAPPED FEATURES 
 EXP. EST.   EXP. ES
T. 
HBA HBA HYA HYA PI 
1 0.089 0.086 -1 8.99 +++ +++ 9 7 25 13 19 
2 2 2.6 +1.3 7.50 ++ +++ 5 8 28 18 23 
3 4 18 +4.4 6.68 +++ +++ * 9 28 16 26 
4 5.6 6.2 -1.1 7.17 +++ +++ 1 10 * 17 12 
5 7.4 11 +1.4 6.90 +++ +++ 4 24 * 12 7 
6 8.7 98 +11 5.93 +++ +++ * 8 * 11 9 
7 12 14 +1.1 6.79 +++ +++ * 17 29 15 17 
8 17 140 +8.7 5.76 +++ +++ 19 * 8 22 2 
9 20 55 +2.7 6.18 ++ ++ 12 * * 26 20 
10 40 220 +5.6 5.58 ++ ++ * * 18 16 11 
11 62 81 +1.3 5.87 ++ ++ * 12 * 18 17 
12 78 140 +1.7 5.79 ++ ++ 21 19 22 * * 
13 85 110 +1.3 5.87 ++ ++ 10 * * 5 13 
14 100 180 +1.8 5.67 ++ ++ 2 7 * 24 * 
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15 120 100 -1.2 5.92 ++ ++ 5 * * 25 18 
16 180 96 -1.9 5.94 ++ ++ 12 * * 26 4 
17 260 130 -2 5.81 + + 12 * * 20 22 
18 390 78 -4.9 6.03 + + * 13 * 28 12 
19 470 110 -2.2 5.87 + + 7 6 * * 18 
20 600 520 -1.2 5.21 + + 9 * 27 * 10 
21 870 3800 +4.4 4.34 + + 11 * * 5 13 
22 2200 150 -14 5.75 + + * 14 20 * 23 
23 4400 1800 -2.4 4.67 + + 8 1 10 * * 
24 8800 110 -77 5.86 + + 15 * * 17 12 
 
• ‘+’ indicates that the predicted IC50 is higher than the experimental IC50 ;’-‘ 
indicates that the predicted IC50 is lower than the experimental IC50, a value of 1 
indicates predicted IC50 is equal to the experimental IC50. 
• Fit value indicates how well the features in the Pharmacophore overlap the 
chemical features in the molecule. 
• Activity scale: c<20nM=+++(highly active); IC50 20-200nM=++(moderately 
active); IC50>200nM=+(low active) 
PHARMACOPHORE VALIDATION42: 
The main purpose of validating a quantitative model is to determine whether our model is 
able to identify active structures and forecast their activity accurately. 
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TEST SET PREDICTION42: 
             The predictive power of the Hypo1 was validated with 24 test set compounds. All 
the compounds were imported into spreadsheet of hypothesis generation workbench and 
activities were estimated. Table 5b lists the Hypo-1 activity values of test set compounds. 
Most of the compounds in the test set were predicted correctly for their biological activity. 
A correlation coefficient of 0.821441 shows a good correlation between the actual and 
estimated activities. 
FISCHERS RANDOMISATION METHOD42: 
Fischers randomization method was used to evaluate the statistical relevance of the model. 
In this test, using Cat Scramble program, the experimental activities in the training set was 
scrambled randomly, and the resulting training set was used for a Hypogen run. All the 
parameters was adopted from the initial Hypogen calculation. This procedure was repeated 
19 times. None of the outcome Hypotheses has lowest cost score than the initial 
hypothesis. Accordingly this result indicates that there is a 99% chance for the best 
Hypothesis to present a true correlation in the training set activity data. 
DECOY SET42: 
Goodness of Hit44: 
The Guner-henry (GH) scoring method was used to assess the quality of Pharmacophore 
models. The GH score is a measure for qualifying the precision of hits and the recall of 
actives mined from a database consisting of known actives and in-actives. It is considered 
as relevant metric, as it takes into account with the percent yield of actives in a database 
(%Y), and the percent ratio of actives in the hit list (%A, precision). The GH score ranges 
from 0, which indicates the null model, to 1, which indicates the ideal model. 
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Enrichment factor: 
      Enrichment factor indicates the quality of the model and high efficiency of the 
screening test. 
     The Hypo-1 was further validated for the ability to pick DPP4 inhibitors in a known 
database. Output of GH score calculation is presented on table 5c.For this validation 
experiment the database of compounds containing 201 inhibitors of DPP4 was taken. This 
database was screened with Hypo-1, 77 molecules was retrieved as hits (Ht).Among these   
molecules were from known actives (Ha). The calculated Goodness of hit (GH) score and 
Enrichment factor for Hypo-1 were 0.89 and 2.69 respectively. The false positives and 
false negatives are 4 and 10.Thus it retrieved 64 of actives from the database predicting 
validity of the model.                                         
Table: 5c 
     Statistical parameter from screening test set molecules 
No PARAMETER VALUES 
1 Total compounds in database (D) 201 
2 Total Number of actives in database 64 
3 Total Hits(Ht) 70 
4 Active Hits(Ha) 60 
5 %Yield of Actives 85.71 
6 %Ratio of actives in the Hit list 93.75 
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7 Enrichment factor or Enhancement(E) 2.69 
8 False Negatives 4 
9 False Positives 10 
10 GH score(Goodness of Hit list) 0.81 
 
5.1.2 DOCKING STUDIES (Glide) 45: 
DOCKING AND SCORING METHODS45: 
                  Docking procedure aims to identify the correct binding poses within the binding 
site of the protein while the scoring function aims to predict binding affinity of ligand for 
the protein binding region. The scoring function serves three purposes. 
1) For ranking the conformations generated by the docking, search for one ligand 
interacting with a given protein, this aspect is essential to detect the best binding 
mode. 
2) For ranking different ligands with respect to binding to one protein i.e. prioritizing 
ligands according to their affinity, this aspect is essential in virtual screening. 
3) For ranking one or different ligands with respect to their binding affinity to 
different proteins their aspect is essential for the consideration of specificity and 
selectivity. 
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STEPS IN DOCKING: 
PROTEIN PREPARATION 45: 
A typical PDB file consists only of heavy metals, can contain waters, cofactors and metal 
ions and can be multimeric. The structure generally has no information on bond orders, 
topologies, or formal atomic charges. Terminal groups can also be misaligned, because the 
X-ray structure analysis cannot easily distinguish between O and NH2 ion. Ionization and 
tautomeric states are usually unassigned. Glide calculations use an all atom force-field for 
accurate energy evaluation. Thus, Glide requires bond orders and ionization states to be 
properly assigned and performs better when side chains are reoriented when necessary and 
steric clashes are relieved. 
The steps by which protein preparation was carried out: 
1. The ligand/protein cocrystallised structure, from PDB was imported into maestro. The 
preparation component of a protein preparation facility requires an identified ligand. 
2. The protein-ligand complex is identified for its form as dimer or other multimer 
containing duplicate binding sites and duplicate chains that are redundant, remove 
redundant binding 
sites and the associated chains by picking and deleting molecules or chains. 
3. The waters that bridge between the ligand and protein are retained and all the other 
waters (except those coordinated to metals) are deleted. If waters are added then hydrogen 
will be automatically added and the orientations of water molecules are checked once 
again. 
4. The protein, metal ions and cofactors are adjusted. Structures that are missing residues 
near the active sites should be repaired. Covalent bonds from metal ions to the protein 
should be changed to zero-order bonds, and the formal charges on the metal and the 
ligating groups should be adjusted to appropriate values. 
45 
Department of Pharmaceutical Chemistry 
5. The ligand bond orders and formal charges are adjusted. Glide models such interactions 
as vanderwaals plus electrostatic interactions. 
6. A restrained minimization of the protein structure reorients side chain hydroxyl groups 
and alleviates potential steric clashes. The minimization is restrained to the input protein 
coordinates by a user-selected RMSD tolerance. 
                     
             5(e)     Crystal structure of Dipeptidyl Peptidase IV inhibitor: 2QOE 
 
LIGAND PREPARATION45: 
Ligand preparation is designed to prepare high quality, 3D structures for large numbers of 
drug like molecules. The structures that are docked must have actual ligand structures and 
should meet the following conditions: 
1. They must be three dimensional. 
2. They must have realistic bond lengths and bond angles. 
3. They must each consist of a single molecule that has no covalent bonds to the receptor, 
with no accompanying fragments, such as counter ions and solvent molecules. 
4. They must have all their hydrogens. 
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5. They must have an appropriate protonation state for physiological pH values (around 7). 
The LigPrep process consists of a series of steps that perform conversions, apply 
corrections to the structures, eliminate unwanted structures, and optimize the structures. 
The simplest use of LigPrep produces a single low-energy 3D structure with correct 
chiralities for each successfully processed input structure. LigPrep can also produce a 
number of structures from each input structure with various ionization states, tautomers, 
stereochemistries, and ring conformations, and eliminate molecules using various criteria 
including molecular weight or specified numbers and types of functional groups present. 
RECEPTOR GRID GENERATION45: 
The shape and properties of the receptor are represented on a grid by several different sets 
of fields that provide progressively more accurate scoring of the ligand poses. For 
receptors that adopt more than one conformation on binding, grids must be prepared for 
each conformation to ensure that possible actives are not missed. 
 The receptor grid defines the receptor structure by excluding any co-crystallised ligand 
that might be present, determine the position and the size of the active site as it will be 
represented by receptor grids, set up glide constraints, and set up flexible hydroxyl groups. 
Receptor grid generation requires a prepared structure: an all-atom structure with 
appropriate bond orders and formal charges. 
LIGAND DOCKING45: 
     Glide ligand docking jobs require a set of previously calculated receptor grids and one 
or more ligand structures. The ligand structures must satisfy the conditions listed above. 
Information on setting up grid generation jobs is given above. Preparation of the ligands 
before docking is strongly recommended. LigPrep or macro Model can be used to prepare 
ligands. If a correct lewis strucuture cannot be generated for a ligand, it is skipped by the 
docking job. 
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DOCKING OF DPP-IV45: 
                     Crystal structure of DPP-4 (PDB code-2QOE) was used for the study. The 
3D structures was downloaded from the Protein Data Bank (PDB) and loaded to the 
Maestro® workbench. The hydrogen atoms were added to the proteins and further 
minimization was performed using protein preparation wizard. Structure based docking 
studies were carried out using GLIDE on DPP4 inhibitors to the 3D structure of DPP4 
and generated 10 best docking poses. During the docking, Glide initially performs a 
complete systematic search of the conformation, orientation, and position of a 
compound in the defined binding site and eliminates unwanted poses using scoring and 
energy optimization. The best poses were selected based on the scoring functions and 
quality of pose orientation within the active site amino acids. Molecules selected for 
synthesis were examined from this docking score which is having high dock value. 
                       
                  5(f)                                                                     5(g) 
   5 (f),(g) Docked molecule in the cocrystal of DPP-4 receptor in ribbon form 
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COCRYSTAL AND DOCKING45: 
Cocrystal and docking is the conformational comparison of these two ligands having 
similar binding modes at the DPP IV binding site. 
Crystal structure of DPP4 (Pdb code: 2 QOE) was downloaded from the Protein data bank 
into the maestro workspace. The protein was split by molecule and generates the cocrystal. 
The cocrystal alone was subjected to Ligprep. The output file was further docked and 
generates docked conformations.  
 
                               
                                           Fig:   5(h)          Cocrystal and docked orientation 
INTERACTIONS45: 
Binding mode of compound SR A, SR B, SR C and SR D in the active site of DPP-4. 
Carbon atoms of the protein and the ligand are indicated in gray. Each dotted line indicates 
a hydrogen bond. 
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             5(i)                                                                                           5(j) 
                 
                  5(k)                                                                             5(l) 
5(i) Interaction between protein and ligand SR A 
5(l) Interaction between protein and ligand SR B 
5(j) Interaction between protein and ligand SR C 
5(k) Interaction between protein and ligand SR D 
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XP DOCKING45: 
 
 
XP TERM DESCRIPTION 
G score Total Glide Score; sum of XP terms 
Lipophilic evdW Lipophilic term derived from hydrophobic 
grid potential and fraction of he total protein 
ligandvdW energy 
PhobEn Hydrophobic enclosure reward 
PhobEnHB Reward for hydrophobically packed H-bond 
PhobEnPairHB Reward for hydrophobically packed 
correlated H-bonds 
Hbond Chem Score H-bond pair term 
Electro Eletrostatic rewards 
SiteMap Sitemap ligand/receptor non-H bonding 
Ligand  G Score Lipophilic 
Evdw 
PhobEn PhobEn 
HB 
PhobEn 
PairHB 
H bond Elect Site 
map 
Pi 
Cat 
ClBr Low 
Mw 
1 -10.34 -3.71 -1.22 -1.5 0 -1.36 -0.82 -0.03 0 0 -0.19 
2 -6.36 -3.97 -1.55 0 0 -0.9 -0.11 -0.4 0 0 -0.38 
3 -6.16 -4.08 -1.7 0 0 -0.35 -0.13 -0.26 0 0 -0.13 
4 -6.04 -4.67 -1.20 0 0 0 -0.23 -0.31 0 0 -0.19 
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polar/hydrophobic and 
hydrophobic/hydrophilic complementarity 
terms 
LowMW Reward for ligands with low molecular 
weight 
Penalties Polar atom burial and desolvation penalties, 
and penalty for intra-ligand contacts 
HBPenal Penalty for ligands with large hydrophobic 
contacts and low H-bond scores 
PhobicPenal Penalty for exposed hydrophobic ligand 
groups 
RotPenal Rotatable bond penalty 
 
 
 
 
 
 
 
SYNTHESISED MOLECULES WITH DOCKING SCORE: 
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N
N N
N
N
N
Cl
Cl
Cl
N
N N
N
N
N
NH2
Cl
Cl
N
N N
N
H
N
N
Cl
Cl
N
O
NH
N
-6.07
-6.16
-6.36
-10.34
 
DRUG LIKENESS SREENING: 
DRUG-LIKE PROPERTIES: 
The properties which can differentiate drugs from other chemicals can be considered as 
drug like properties. Drug-likeness is a qualitative concept used in drug design for how 
drug like substance is to be an effective drug, a substance must be characterised by optimal 
solubility to both water and fat. Orally administered drugs must pass through the intestinal 
lining and be transported in aqueous blood, then penetrate the lipid cellular membrane to 
reach the inside of a cell. The model compound for cellular membrane is octanol, so the 
logarithm of the octanol/water partition coefficient, known as logP is used to estimate 
solubility. 
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Since the drug is transported in an aqueous media like blood and intracellular fluid, it 
has to be sufficiently water-soluble. Solubility in water can be estimated from the number 
of hydrogen bond donors vs. the alkyl side chains in the molecule. Low water solubility 
translates to slow absorption and action. Too many hydrogen bond donors, on the other 
hand, leads to low fat solubility, so the drug cannot penetrate the cell wall. 
The lower the molecular weights, the better molecule .A total of 80% of the drugs have 
molecular weight under 450 dalton. 
LIPINSKIS RULE47: 
Lipinski’s rule was formulated by Christopher A. Lipinski in 1997, based on the 
observation that most medication drugs are relatively small and lipophilic molecules. As a 
rule of thumb, orally absorbed drugs tend to obey Lipinski’s rule of five. The rule of five 
was derived from the analysis of compounds from the World Drugs Index database, aimed 
at identifying features that were important in making a drug orally active. 
The factors concerned involved numbers that are multiples of 5: 
1. A molecular weight less than 500 
2. No more than 5 hydrogen bond donor groups 
3. No more than 10 hydrogen bond acceptor groups 
4. A calculated log P value less than +5 (log P is a measure of a drug’s 
hydrophobicity) 
The rule describes molecular properties important for a drugs pharmacokinetics, 
including Absorption, Distribution, Metabolism and Excretion. It is to evaluate drug 
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likeness or determine if a chemical compound with a certain pharmacological or 
biological activity has properties that would make it a likely orally active drug. 
COMPOUND Log 
P 
Mol.Wt TPSA nOHNH nON No. of 
rotatable 
bonds. 
No. Of 
violations 
SRI A 1.72 C14H7Cl3N6 
 
61.436 0 6 2 0 
SRI B 0.118 C14H11Cl2N7 
 
87.459 2 7 2 0 
SRI C 1.929 C12H10N20 
 
41.99 1 3 2 0 
SRI D 0.276 C8H4Cl2N6 
 
67.664 2 6 1 0 
 
 
 
 
 
SYNTHESIS: 
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PURINES AND PYRIDINES [48, 49] 
A purine is a heterocyclic aromatic organic compound, consisting of a pyrimidine ring 
fused to an imidazole ring of molecular formula C5H4N4. Purines including substituted 
purines and their tautomers, are the most widely distributed kind of nitrogen-containing 
heterocycle in nature. Purines and pyrimidines make up the two groups of nitrogenous 
bases, including the two groups of nucleotide bases.                                       
                                                           
N
N N
N
H
 
                  Pyridine is a basic heterocyclic compound containing one nitrogen atom and 
five carbon atoms in its molecules with molecular formula C5H5N.  It is used as a solvent 
and waterproofing agent and in the manufacture of various drugs and vitamins. 
                                                                   
N
 
TAUTOMERS OF PURINE: 
Purine can exist in four tautomeric forms in which the hydrogen atom is joined to different 
nitrogen atoms: N-1, N-3, N-7, and N-9. In the first two the aromaticity of the pyrimidine 
ring is lost, the ring now being virtually equivalent to the far less stable (and more reactive) 
ortho-quinonoid structure. In practice, purine appears to behave completely as the 
tautomers of N-7 H and N-9 H. 
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SYNTHESIS OF PURINES: 
The purine ring system is a fusion of two aromatic heterocycles, pyrimidine and 
imidazole. The starting point for the ring synthesis is substituted pyrimidine or imidazole 
from which the second ring can be constructed by a cyclisation process. Both of these 
methods have been used for the synthesis of purines. 
METHOD A:  
The most common method is the Traube’s synthesis. This is a versatile method 
because of the variety of substituents possible in both components. Formic acid was 
originally used as the cyclisation reagent; its reaction with 2, 5, 6-triaminopyrimidin-4-one 
gave guanine by way of the intermediate, N-formyl derivative. 
N
NH
NH2
NH2
NH2
O
N
NH
NH2
NHCHO
NH2
O
N
NH N
N
H
O
NH2
HCOOH
heat
 
Formamide, formamidine, ethyl orthoformate and similar electrophilic reagents can 
be used in place of formic acid in this type of synthesis.8-substituted purines can be 
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constructed by using a different type of acylating agent such as acetic anhydride. When the 
diamino pyrimidines are heated with urea, 8-oxopurines are formed. 
 
N
N
NH2
NH2 N
N
NHCOMe
NH2 N
N N
N
H
Me
Ac2O
heat
pyrimidine-4,5-diamine N-(4-aminopyrimidin-5-yl)acetamide 8-methyl-9H-purine
 
 
N
H
NH
NH2
NH2
O
O N
H
NH
NHCONH2
NH2
O
O N
H
NH N
H
N
H
O
O
O
Ac2O
heat
5,6-diaminopyrimidine-2,4(1H,3H)-dione 7,9-dihydro-1H-purine-2,6,8(3H)-trione
 
METHOD B: 
The synthesis of purines by route (b) is a useful alternative to that based on 
diaminopyrimidines. 5-Aminoimidazole-4-carboxamide and related compounds are 
commonly used as precursors. 
  For example, the carboxamide can be formylated with formic acid and the formamide is 
cyclised on heating.This method of synthesis is closely related to the biological route to 
purines: 5-aminoimidazole-4-carboxamide occurs naturally (as ribonucleotide) and it is the 
precursor of the purine nucleotides. 
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N
H
N
H2NOC
NH2 N
H
N
H2NOC
OHCHN
N
NH N
N
H
O
HCOOH
heat
heat
5-amino-1H-imidazole-4-carboxamide 1,9-dihydro-6H-purin-6-one
 
SYNTHESIS OF PYRIDINES AND RELATED COMPOUNDS: 
CHICHIBABIN SYNTHESIS: 
The Chichibabin pyridine synthesis is a condensation reaction of aldehydes, 
ketones and α,β unsaturated carbonyl compounds, or any of the combination of the above, 
in ammonia or ammonia derivatives. 
                                 
HANTZSCH PYRIDINE SYNTHESIS: 
This reaction allows the preparation of dihydropyridine derivatives by condensation 
of an aldehyde with two equivalents of a β-ketoester in the presence of ammonia. 
Subsequent oxidation (or dehydrogenation) gives pyridine-3, 5-dicarboxylates, which may 
also be decarboxylated to yield the corresponding pyridines. 
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BONNEMANN CYCLIZATION: 
The trimerization of a part of a nitrile molecule and two parts of acetylene activated 
either by heat or light into pyridine is called Bonnemann cyclization. While the thermal 
activation requires high pressures and temperatures, the photo induced cyclo addition 
proceeds at ambient conditions with CoCp2 (cod) (Cp = cyclopentadienyl, cod = 1, 5-
cyclooctadiene) as a catalyst, and can be performed even in water.  
 
 
 
 
REACTIONS OF PURINES: 
1. Purines can be N-alkylated and N-oxidized but the site of reaction is dependent upon the 
substituent’s present and the reagent.  
Purine is converted into 9-methylpurine by reaction with dimethyl sulphate in aqueous 
solution 
                            
N
N N
N
H
N
N N
N
R
Alkylation
in aqueous solution
9H-purine N-Alkylated purine
 
2. Reaction of oxoderivatives with phosphorous oxychloride gives chloropurines.Chlorine 
is more easily displaced at C-6 than at C-2. 
2,6-dichloropurine gives 6-amino-2-chloro purine with methanolic ammonia at 100°C. 
N
CH
CH
+ NHC +
CH
CH
red hot tube
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N
N N
N
H
Cl
Cl N
N N
N
H
NH2
Cl
NH3/MeOH
1000C
2,6-dichloro-9H-purine 2-chloro-9H-purin-6-amine
 
 
 3. With 2,6,8-trichloropurine, the chloride at C-8 is the least easily displaced in alkaline 
media because the proton at the adjacent nitrogen atom is removed by the base. 
                            
N
N N
N
Cl
Cl
Cl
R
N
N N
H
N
Cl
Cl
O
R
NaOH aq.
 
           Examples of selective displacement of chloride 
4. The six-membered ring system of purines also undergoes some of the other reactions 
such as photoaddition reactions across N-1 and C-6 and nucleophilc ring cleavage. 
An example of nucleophilic cleavage is the Dimroth rearrangement of a 1-alkylated 
adenine. 
                  
N
RN+ N
N
H
NH2
N
N N
N
H
NHR
NaOH
800C
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REACTIONS OF PYRIDINES: 
          1.  ELETROPHILIC SUBSTITUTION: 
 
 
 
 
           2. NUCLEOPHILC SUBSTITUTION REACTIONS: 
 
i) Reaction with Organometallic compounds Lithium Reagents: 
                      
 
 
                Reaction with Potassium Hydroxide: 
                 
 
 
 
N
+ C4H9Li
N C4H9Butyllithium
2-Butylpyridine
N
KOH / 320 C
N O N
H
OH
2-Pyridone2-Hydroxy pyridine
° keto-enol
tautomerism
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REDUCTION REACTIONS: 
 
 
 
 
 
GENERAL SYNTHETIC PROCEDURE: [47, 48, 49] 
Ligand based and structured based docking studies led to the identification of 25 
molecules with high glide score and interactions. Four molecules that were synthetically 
feasible were selected and synthesised and labelled as SR A, SR B, SR C and SR D 
2,8-dichloro-9-(4-chlorophenyl)-6-(1H-imidazol-1-yl)-9H-purine- SR A 
4-[2,8-dichloro-6-(1H-imidazol-1-yl)-9H-purin-9-yl]aniline- SR B 
2,8-dichloro-6-(1H-imidazol-1-yl)-9H-purine- SR C 
N-(pyridin-4-yl) pyridine-3-carboxamide- SR D 
 
SYNTHETIC PROCEDURE FOR PURINE: 
There have been numerous investigations on the synthesis of purine ring which is the 
base component of nucleic acids, major methods of the purine synthesis being as follows: 
(a) Cyclization of 4,5-diaminopyrimidine with anhydrous formic acid in the carbon 
monoxideatmosphere 
N
1) L
iAl
H 4
2) H
+  , 
H 2
O
Na/NH
3
Birch
 reduction
H
2 /Ni
HI
, 
300
o C
N
H
N
H
N
H
CH3CH2CH2CH2CH3+ NH3
1,4-Dihydropyridine
1,2-Dihydropyridine
piperidine
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1)(b) Reaction of tris(formylamino) methane with phthalimidacetonitrile at high 
temperature 
2)(c) Reaction of aminoacetonitrile with formamide 
3)(d) Reaction of formamide and glycine or glycineamide with phosphorus oxychloride in 
a sealed tube. 
These synthetic methods have various handicaps such as the low yield of product and 
complex procedures. 
PROCEDURE FOR THE SYNTHESIS OF COMPOUND SR C, SR A and SR B: 
STEP 1:  
Synthesis of 2, 6, 8-trichloro-9H-purine: 
CHLORINATION PROCEDURE: 
Phosphorus oxychloride and a nitrogenous base were added to uric acid in the 
molar ratio of 10:3:1 respectively. The phosphorus oxychloride was freshly distilled, the 
amine was dried over potassium hydroxide, while the uric acid was dried over phosphorus 
pentoxide prior to use. The reaction mixture was refluxed with the exclusion of moisture 
and with stirring for 20-24 hours. Distillation of the resultant solution under reduced 
pressure to about half volume yielded a syrupy reaction mixture. 
ISOLATION PROCEDURE: 
The syrupy reaction mixture was poured slowly over the crushed ice. Ice was added 
periodically to the hydrolysis mixture to maintain a few suspended pieces in the solute, 
thus assuring low temperatures at all times; the tar was triturated frequently to hasten the 
conversion to a more granular solid. Approximately after one hour the mixture and the 
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aqueous filtrate were extracted with six portions of ether which were then used to extract 
the solid. 
The ether extracts were combined and evaporated to dryness yielding a solid 
residue which was extracted with minimum of boiling 3N ammonium hydroxide and 
filtered. The insoluble portion was fraction 1 c. Upon cooling the filtrate, ammonium salt 
of 2, 6, 8-trichloropurine was yielded as a mass of fine needles. Neutralization of the 
mother liquor precipitated a small amount of crude 2, 6, 8-trichioropurine. 
STEP: 2  
  Synthesis of  2, 8-dichloro-6-(1H-imidazol-1-yl)-9H-purine (SR C): 
       The 6-chloro function of 2, 6-dichloropurine can be region selectively replaced by 
imidazole in DMF at 65 oC to give the product. It is well known that the 6-chloride is much 
more readily replaced than the 2-Cl group. 
        2,6-Dichloropurine ( 2 mmol) and imidazole (12.1 mmol) were dissolved in freshly 
distilled DMF (36 mL), and the mixture was stirred at 65oC for ~20h. Volatiles were 
evaporated, and the residue was washed with a large amount of CH2Cl2 to give SR C 
(66%). 
STEP:3 FROM SR C-SYNTHESIS OF  SR-A: 
Synthesis of 2, 8-dichloro-9-(4-chlorophenyl)-6-(1H-imidazol-1-yl)-9H-purine: 
      A mixture of 0.22 mol of 2,8-dichloro-6-(1H-imidazol-1-yl)-9H-purine, 0.22 mol  of 
anhydrous potassium carbonate, and 0.20 mol of 1,4-dichloro benzene in 400 ml of 
Dimethyl formamide were stirred at ambient temperature for 64 hours. The reaction 
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mixture was poured into ice water with stirring and the solid that precipitated was collected 
by filtration. 
FROM SR C -SYNTHESIS OF SR-B: 
Synthesis of 2, 8-dichloro-6-(1H-imidazol-1-yl)-9H-purine: 
         A mixture of 0.22 mol of 8-dichloro-6-(1H-imidazol-1-yl)-9H-purine, 0.22 mol of 
anhydrous potassium carbonate, and 0.20 mol of 4-chloro aniline  in 400 ml of Dimethyl 
formamide was stirred at ambient temperature for 64 hours. The reaction mixture was 
poured into ice water with stirring and the solid that precipitated was collected by 
filtration. 
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9H-purine-2,6,8-triol
2,6,8-trichloro-9H-purine
2,8-dichloro-6-(1H-imidazol-1-yl)-9H-purine
4-[2,8-dichloro-6-(1H-imidazol-1-yl)-9H-purin-9-yl]aniline 2,8-dichloro-9-(4-chlorophenyl)-6-(1H-imidazol-1-yl)-9H-purine
 
 
 
Synthesis of  N-(pyridin-4-yl) pyridine-3-carboxamide: [54] 
   2-amino pyridine in pyridine solvent showed that the reaction with pyridine-2-carbonyl 
chloride gives derivatives by direct reaction on the exocyclic nitrogen. 25ml pyridine-2-
carbonyl chloride was added drop wise to 2-amino pyridine and dissolved in pyridine 
solvent. The reaction is maintained at lower temperatures and was accelerated by addition 
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of few drops of DMF. The resulting reaction mixture was poured into cold water and white 
crystals were formed and isolated. It was recrystallized. 
N
Cl
O
N
N
O
H
N
N
DMF
H2N
 
    pyridine-2-carbonyl chloride                                               N-(pyridin-2-yl)pyridine-2-carboxamide 
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CHARACTERISATION: 
INSTRUMENTATION: 
The techniques employed for the characterization of the synthesised compounds 
were UV spectra, IR spectra,1H-NMR spectra and elemental analysis  . 
UV SPECTROSCOPY: 
UV-Visible spectroscopy involves the measurement of amount of UV radiation absorbed 
by a substance in the solution. The wavelength between 200-400nm is considered to be UV 
radiations or UV region. Colored compounds absorb in visible range (i.e.) 400-800nm.The 
UV spectrum of an organic compound helps  
• To make the research procedure easy and accurate 
• To determine the concentration of drug, compounds in the media 
• To determine impurity 
• For quantitative analysis of compounds 
• To determine geometrical isomer 
INFRA RED SPECTROSCOPY: 
The vibrational spectrum of a molecule is considered to be a unique physical 
property and is characteristic of the molecule. As such, the infrared spectrum can be used 
as a fingerprint for identification by the comparison of the spectrum from an ‘‘unknown’’ 
with previously recorded reference spectra. This is the basis of computer-based spectral 
searching. In the absence of a suitable reference database, it is possible to effect a basic 
interpretation of the spectrum from first principles, leading to characterization, and 
possibly even identification of an unknown sample. This first principle approach is based 
on the fact that structural features of the molecule, whether they are the backbone of the 
molecule or the functional groups attached to the molecule, produce characteristic and 
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reproducible absorptions in the spectrum. This information can indicate whether there is 
backbone to the structure and, if so, whether the backbone consists of linear or branched 
chains. Next it is possible to determine if there is unsaturation and/or aromatic rings in the 
structure. Finally, it is possible to deduce whether specific functional groups are present. If 
detected, local orientations of the group and its local environment and/or location in the 
structure are determined. 
 
1H - NMR MAGNETIC RESONANCE SPECTROSCOPY: 
Proton Nuclear Magnetic Resonance (1H NMR) Spectroscopy is a powerful method used 
in the determination of the structure of unknown organic compounds. The 1H NMR 
spectrum of an organic compound provides information concerning: 
1) Number of Signals --- indicates how many "different kinds" of protons are present. 
2) Positions of the Signals --- indicates something about magnetic (electronic) environment 
of protons. 
3) Intensities (areas) of the Signals --- proportional to number of protons present. 
4) Splitting of a Signal into Several Peaks --- indicates the number of nearby nuclei having 
magnetic moments (usually protons, sometimes fluorine). 
        Proton NMR Spectra were recorded using solvent Deutrated methanol on BRUKER. 
Advance III 500 NMR spectrometer. Chemical shifts are reported in parts per million 
(ᵟppm).  
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MASS SPECTROMETRY: 
Mass spectrometry (MS) is an analytical technique that measures the mass-to-charge 
ratio of charged particles. It is used for determining the masses of particles, for determining 
the elemental composition of a sample or molecule, and for elucidating the chemical 
structure of molecules. 
 It determines molecular mass by manipulating flight path of molecular ion (or fragments) 
in magnetic field. The mass spectra of an organic compound provide information 
concerning: 
M     : reveals mass of molecule consisting of lowest mass isotopes 
M+1: intensity / 1.1% give approximate number of carbons 
M+2: intensity reveals presence of S, Cl or Br 
The compounds were found to have  
1. Ultraviolet spectroscopy (UV) by Shimadzu UV-Spectrophotometer. 
2. Infrared spectroscopy (IR) by Perkin-Elmer Spectrometer usin KBr pellets. 
3. Nuclear Magnetic Resonance spectroscopy (1HNMR) by 500MHZ JEOL using 
DMSO. 
4. Mass spectroscopic (MS) by JEOL GC mate. 
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PHYSICAL DATA: 
Synthesis and identification of purine and pyridine derivatives: 
COMPOUND 
NO. 
        SR A         SR B     SR C          SR D 
PRODUCT 
N
N N
H
N
N
N
C l
C l
C l
 
N
N N
H
N
N
N
Cl
Cl
NH2
 
N
N N
H
N
H
N
N
C l
C l
 
N NH
O N
 
RECRYSTALL
ISATION 
 Ethanol Ethanol Ethanol Ethanol 
YIELD(%) 75 70 78 80 
Melting Point 2220C 2100C 2300C 1920C 
TLC:     
Stationary 
Phase 
Precoated silica gel 
GF plates 
Precoated silica 
gel GF plates 
Precoated silica gel GF 
plates 
Precoated silica 
gel GF plates 
Mobile Phase Methanol/Chlorofor
m 
Methanol/Chlor
oform 
Methanol/Chloroform Methanol/Chloro
form 
Location UV Chamber UV Chamber UV Chamber UV Chamber 
UV 
SPECTROSCO
Y: 
    
  289nm 295nm 291nm 279nm 
IR 
SPECTROSCP
Y: 
    
 3000-3100cm-1(C-
H), 1389cm-
1(C=C),1100 cm-
1(C-N), 3400cm-
1(Ar- NH2)N-H, 
1300cm-1Ar-
3000-3100cm-
1(C-H),1389cm-
1(C=C),1011cm
-1(C-
N),3411cm-
1(Ar-NH2)N-H, 
3070cm-1(C-H), 
1304cm-1(C=C), 
3448cm-1(N-H), 1674 
cm-1(C=O), 1065cm-
1(C-N), 1582cm-
1(C=N). 
3008cm-1(C-
H),1404cm-
1(C=C),1018cm-
1(C-N),1589 cm-1 
(C=N),741cm-
1(C-Cl),1738 cm-
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NH2(C-N). 1300cm-1Ar-
NH2(C-N). 
1(C=O) 
NMR      
 
δ6.8 (d,2H,Aromatic 
C-
H),7.1(d,2H,Aromat
ic C-
H),7.6(d,2H,heteroa
romatic C-
H),8.5(s,1H,heteroa
romatic C-H)-
(Aromatic) 
δ6.8 
(d,2H,Aromatic 
C-
H),7.1(d,2H,Ar
omatic C-
H),7.6(d,2H,het
eroaromatic C-
H),8.5(s,1H,het
eroaromatic C-
H)-
(Aromatic),10.5
(s,2H,-NH2) 
6.9(s,1H,Aromatic C-
H),7.1(s 
2H,Hetroaromatic),8.3(
s,1H,Aromatic C-H) 
7.5(m,8H,hetero
aromatic C-
H),8.6(s,1H,-
NH) 
MASS 
SPECTROSCO
PY 
    
 367.71(M+2), (2%) 
365.61(M+)(5%),63.
22(B) (100%) 
348.43(M+2) 
(2%), 
346.17(M+)(7%
),60.05(B) 
(100%) 
198.38(M+)(12%) 
,106.6(B) (100%) 
235.01(M+)(6%),
60.3(B) (100%) 
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ACUTE TOXICITY54: 
      Acute toxicity is the toxicity produced by a pharmaceutical when it is administered in 
one or more doses during a period not exceeding 24 hours. 
                   Acute toxicity studies in animals are usually necessary for any pharmaceutical 
intended for human use. The information obtained from these studies is useful in choosing 
doses for repeat-dose and studies, providing preliminary identification of target organs of 
toxicity, and, occasionally, revealing delayed toxicity. Acute toxicity studies may also aid 
in the selection of starting doses for Phase 1 human studies, and provide information 
relevant to acute overdosing in humans. 
This acute toxicity study was designed as per the OECD Guidelines for Testing of 
Chemicals, Acute Oral Toxicity (Acute Toxic Class Method),Guideline 423. 
PRINCIPLE OF THE TEST: 
Acute toxicity testing determines the toxicity of a chemical or drug substances after single 
administration. 
       Today, acute toxicity testing focuses on levels on acute tolerance, nature of acute 
toxicity symptoms in the sub-lethal range, and dose levels which cause mortality in two 
animals i.e. quality has replaced quantity. 
  It is the principle of the test that, based on a stepwise procedure with the use of a 
minimum  
number of animals per step, sufficient information is obtained on the acute toxicity of the 
test substance to enable its classification.  The substance is administered orally to a group 
of experimental animals at one of the defined doses. The substance is tested using a 
stepwise procedure, each step using four animals of a single sex (normally females).  
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Absence or presence of compound-related mortality of the animals dosed at one step will 
determine the next step, i.e.; 
• no further testing is needed, 
• dosing of three additional animals, with the same dose 
• Dosing of three additional animals at the next higher or the next lower dose level. 
DESCRIPTION OF THE METHOD: 
EXPERIMENTAL ANIMALS: 
Healthy adult female Albino mice (4nos.) were used in research. Females were weighing 
between 20-25mg, for all the four animals food, but not water withheld overnight prior to 
dosing. 
SELECTION OF DOSE LEVELS & ADMINISTRATION OF DOSES: 
Purine and Pyridine derivatives, being novel synthetic compounds, the mortality was 
unlikely at the highest starting dose level (300mg/kg body weight). Hence a limit test at 
one dose level of 300mg/kg body weight was conducted in all the four animals. 
HOUSING AND LIGHTING CONDITIONS: 
The temperature in the experimental animal room should be 22ºC (+ 3ºC). Although the 
relative humidity should be at least 30% and preferably not exceed 70% other than during 
room cleaning the aim should be 50-60%. Lighting should be artificial, the sequence being 
12 hours light, 12 hours dark. For feeding, conventional laboratory diets may be used with 
an unlimited supply of drinking water. Animals may be group-caged by dose, but  
the number of animals per cage must not interfere with clear observations of each animal. 
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PROCEDURE: 
ADMINISTRATION OF DOSES: 
The test substance is administered in a single dose by 19 guage using an oral tube.  
 
TESTING PROCEDURES: 
  The test compounds should be administered to animal to identify doses causing no 
adverse effects and doses causing major (life-threatening) toxicity. The use of vehicle 
control groups should be considered. For compounds with low toxicity, maximum feasible 
dose should be administered. 
Studies should be conducted in at least two mammalian species, including a non 
rodent species when reasonable. The objectives of acute studies can usually be achieved in 
rodents using small groups of animals (for instance, three to five rodents per sex per dose). 
Where non rodent species are appropriate for investigation, use of fewer animals may be 
considered. Any data providing information on acute effects in non rodent species, 
including preliminary dose-range finding data for repeat-dose toxicity studies, may be 
acceptable. 
OBSERVATION 
The animals were observed individually after dosing once during the first 30 minutes, 
periodically for the first 24 hours , with special attention given during the first 4 hours & 
daily there-after, for a total of 14 days. The following clinical observation were made and 
recorded. 
• Toxic Signs 
All mice were observed for any toxic signs. 
All the rats were observed for any pre terminal deaths. 
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• Body Weight 
         Individual body weights were recorded for all the animals once in a week. 
• Cage Side Observation 
The faeces colour, faeces consistency, changes in skin & fur, eyes & mucous 
membrane (nasal) of the animal were observed once in a week. 
• Physical examination 
Physical examination included changes in,  
 Respiratory System 
 Cardiovascular system(hear rate) 
 Salivation, lacrimation, piloerection, urinary incontinence and defecation. 
 Central nervous system: 
Ptosis, drowsiness, gait, eye prominence, eyelid closure, convulsions, 
biting,staub’s test, motor incoordination, writhing, stereotypy, aggression, 
righting reflex, pinna reflex, corneal reflex,tremors and convulsions. 
 
77 
Department of Pharmaceutical Chemistry 
 
 
 
 
78 
Department of Pharmaceutical Chemistry 
ANTI-DIABETIC ACTIVITY55: 
IN VIVO ANIMAL MODELS OF DIABETES MELLITUS: 
Diabetes can be induced by pharmacologic, surgical or genetic manipulations in 
several animal species. In vivo is the experimentation using a whole, living organism as 
opposed to partial or dead organism. Animal testing and clinical trials are two forms of 
clinical research. In vivo testing is often employed because it is better suited for observing 
the overall effects of an experiment on a living subject. 
PHARMACOLOGICAL INDUCTION OF DIABETES: 
Streptazotocin and alloxan are the most frequently used drugs for the induction of 
Diabetes mellitus. Both drugs exert their diabetogenic action when they are administered 
parentrally, intravenously, intraperitoneally or subcutaneously. The dose of these agents 
required for inducing diabetes depends on the animal species, route of administration and 
nutritional status. According to the administered dose of these agents syndromes similar to 
either type 1, type 2 diabetes mellitus or glucose tolerance can be induced. 
The cytotoxic action of these diabetogenic agents is mediated by reactive oxygen 
species, but both the drugs differ in their mechanism of action. 
Alloxan and the product of its reduction dialuric acid, establish a redox cycle with the 
formation of superoxide radicals. These radicals undergo dismutation to hydrogen peroxide 
with a simultaneous massive increase in cytosolic calcium concentration, which causes 
rapid destruction of pancreatic β cells. The range of diabetogenic dose of alloxan is quite 
narrow and even light overdosing may be generally toxic and may cause the loss of many 
animals. This loss is likely to stem from kidney tubular cell necrotic toxicity, in particular 
when too high doses of alloxan are administered. The most frequently used intravenous 
dose of alloxan in rats is 65mg/kg, but when it is administered intraperitoneally or 
subcutaneously its effective dose must be higher. For instance, an intraperitoneal dose 
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below 150mg/kg may be sufficient for inducing diabetes in the animal species. In mice 
doses vary among 100-200 mg/kg by intravenous route. 
The destruction of pancreatic β cells by alloxan is associated with a huge release of 
insulin which makes animal more sensitive to severe hypoglycaemia that may be lethal. 
Thus following the treatment with alloxan, animals are fed with glucose solution (5%) for 
12-24 hrs.Afterwards an increase of glucose levels is observed in comparison to control 
animals due to insulin deficiency. It is also reported that fasted animals are more 
susceptible to alloxan effects and increased blood glucose in fed animals provides partial 
protection. The experimental protocols recommend that administration of alloxan must be 
done in fasting period (8-12hrs), followed by addition of glucose solution to avoid 
hypoglycaemia. 
EXPERIMENTAL DESIGN: 
Animals   : Swiss albino mice. 
Sex          : Either sex. 
Weight   : 25-30g. 
Groups: 6, six animals each. 
Group 1: Diabetic control – animals receiving alloxan at the dose of 60 mg/kg b.w. 
Group 2: Synthetic compound 1 
Group 3: synthetic compound 2 
Group 4: synthetic compound 3 
Group 5: synthetic compound 4 
Group 6: Animals receiving Glibenclamide at the dose of 3mg/kg b.w. 
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Induction of experimental diabetes 
Diabetes is induced in mice by intraperitoneal (i.p.) injection of alloxan at a dose of 
60mg/kg body weight, dissolved in saline. Diabetes is confirmed by the determination of 
fasting blood glucose concentration on the third day post administration of alloxan.  
 
Evaluation of Anti-Diabetic Activity: 
Blood glucose and urine glucose levels are measured on day 1, 4, 7, 10 and 15 of the study.  
 
1. ESTIMATION OF BLOOD GLUCOSE 
METHOD OF BLOOD COLLECTION: 
Blood sample for glucose estimation was collected from mice tail tip. In a well 
restrained mice, the tail was embedded in hot water 450C and about 1mm of it s end was 
cut and the drop of blood was collected directly on the strip placed in the glucometer (One 
Touch Horizon, Life Scan Inc.Milpitas USA, Johnson and Johnson Company). 
2. ESTIMATION OF URINE GLUCOSE 
Glucose will overflow into the urine only when the blood glucose level is high, that 
is, too high for the kidneys to stop it spilling over into the urine. In most people, blood 
glucose levels above 10 mmol of glucose per litre of plasma will cause glucose to appear in 
the urine. This level is called the ‘renal threshold’ for glucose. 
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PROCEDURE 
Fresh urine was collected by slightly pressing the tail and back of the rat. Glucose and 
ketonein urine was checked using keto-diastix strips 
RESULTS AND DISCUSSION 
The results of the Drug design, Synthesis of compounds and Evaluation of compounds are 
discussed below: 
1) DRUG DESIGN 
        In the Hypogen studies 10 hypotheses were generated using the most diverse 24 
molecules from the training set (Fig.5d) and validated using 201 test molecules. 
Pharmacophore were computed and the top-10 hypotheses were exported. Results of 
Pharmacophore hypotheses are presented in Table 5a. The top ranked one, OutHypo-1 
consists of two hydrophobic Aliphatic and one Positive ionisable features. The quality of 
the generated Pharmacophore hypotheses was evaluated by considering the cost functions 
calculated by Hypogen module during hypotheses generation. The cost values, 
correlation(r) and root mean square deviations (R.M.S.D) values are given in Table 5a. 
Hypo1 is the best Pharmacophore hypotheses in this study, as it is characterized by the 
lowest total cost (116.3) the highest cost difference between the null and total hypotheses 
cost(52.582),the lowest RMSD(1.34256) and the best correlation coefficient(0.821441). It 
is evident that as error, weight and configuration component are very low, the total 
Pharmacophore cost is also low and close to the fixed cost. Also, as total cost is less than 
the null cost, this model accounts for all the Pharmacophore features and has a good 
predictability power.  Fig.5c shows the best Pharmacophore features with their geometric 
parameters. Fig 5b and 5a represents the best Pharmacophore model aligned with the most 
active and inactive molecules with IC50 of 0.089nM and 8800nM respectively.In the Fig 5b 
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the Pharmacophore features are mapped well to the active molecule. On the other hand in 
Fig 5a the feature of the could not fit well since it is a low active molecule. 
                  In the training set, out of eight highly active molecules eight are correctly 
predicted as highly active, out of eight medium active molecules eight  were predicted 
well, and in the eight inactive molecules, eight were predicted to be less activity. It was 
inferred that there is less difference between the experimental and predicted IC50 values 
and thus the error values are less and the fit value gives a gives a good measure of how 
precisely the defined features in the best Pharmacophore fit well with each molecule. 
2) SYNTHESIS AND CHARACTERISATION 
The synthesised compounds were recrystallized and identified by TLC. The melting points 
of the products were found. The characterisation was carried out using sophisticated 
instruments like UV, IR, NMR, MASS spectroscopy. 
UV SPECTROSCOPY 
Electronic Transitions observed in synthesised compounds: 
The synthesized compounds SR A-SR D show R, K&B bands. (n-      ∏*) 
The R-band due to presence of Oxygen and Nitrogen. (∏-       ∏*) 
The K-band is due to conjugated system 
The B-band is due to the presence of aromatic and hetero aromatic systems. 
Presence of auxochrome like OH, NR2, groups in the synthesized compounds are 
responsible for the high intensity absorption and bathochromic shifts. 
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IR SPECTROSCOPY: 
The IR Spectra have been used to identify the synthesised compounds. 
The presence of impurities like the starting raw materials uric acid, 1, 4-dichloro benzene 
and 4-chloro aniline were ruled out. 
The synthesised compounds show the following specific characteristic stretching and 
bending vibration. 
3400-3100 cm-1 stretching vibration of N-H group. 
3100-3000 cm-1 stretching vibration of Aromatic ring. 
Formation of the purine nucleus has been confirmed by the following characteristic 
regions: 
1400-1000 cm-1 bending vibration of C-N group. 
Presence of impurities: 
The presence of starting materials as impurity was ruled out by observing the following 
characteristic stretching region:  
Absence of stretching in the region of 3650-3584 cm-1 indicates the absence of OH group. 
NMR SPECTROSCOPY: 
The 1H NMR Spectral data of all the synthesised compounds were in conformity with the 
structure assigned. All the compounds showed peak in the region 6-9ppm proving the 
presence of Aromatic protons. The peak in the region of 8.6, 7.2 observed the presence of 
specific protons NH&CH.A common peak appears in all spectra in the region of 1 to 2 
ppm. This implies the solvent peak. 
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MASS SPECTROSCOPY: 
The entire synthesised compounds exhibited molecular ion peak (M+) of varying 
intensities ascertains the molecular weights of the compounds. Compound SR A, SR B and 
SR C shows M+2 peak due to the presence of Cl. 
All the above data confirmed the assigned structure of the synthesised compounds. 
PHARMACOLOGICAL EVALUATION: 
ACUTE TOXICITY: 
Acute oral toxicity was performed according to the OECD guidelines 423A method. 
This method has been designed to evaluate the substance at fixed doses and provides 
information both for hazard assessment and substance to be ranked for hazard 
classification purposes. 
The synthesised compounds were administered initially at a starting dose of  5mg/kg body 
weight in 1% CMC (p.o) and observed 14 days mortality due to acute toxicity. 
Careful observation was made at least twice a day for the effect on CNS, ANS, motor 
activity, salivation, skin coloration and other general signs of toxicity were also observed 
and recorded. 
Since no sign of toxicity was observed at 50mg/kg body weight to the group of animals, 
the LD50 value of the title compounds (SR A-SR D) expected to exceed 50mg/kg body 
weight and represented as class 2. 
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From the toxicity studies the data revealed that all the synthesised compounds proved to be 
non toxic at tested dose level and well tolerated by the experimental animals as their LD 50 
cut –off values > 50mg/kg body weight.  
Pre-terminal deaths: 
S. No PARAMETER 4hr 24hr 48hr 7day 14day 
1 Salivation Normal Normal Normal Normal Normal 
2 Lacrymation Normal Normal Normal Normal Normal 
3 Respiratory rate Normal Normal Normal Normal Normal 
4 Colour of the 
eye` 
Normal Normal Normal Normal Normal 
5 Inflammation Absent Absent Absent Absent Absent 
6 Jumping Absent Absent Absent Absent Absent 
7 Grooming Absent Absent Absent Absent Absent 
8 Gnawing Absent Absent Absent Absent Absent 
9 Straubs Tail 
effect 
Absent Absent Absent Absent Absent 
10 Fur colour Normal Normal Normal Normal Normal 
11. Aggression Absent Absent Absent Absent Absent 
12 Anxiety Absent Absent Absent Absent Absent 
13 Colour of faces Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal 
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ANTI-DIABETIC ACTIVITY: 
Effects of various compounds on glucose levels: 
GROUPS DAY 0 DAY 7 DAY 14 
GROUP I 83.00±1.41 
 
 
92.25±2.06* 
 
 
111.50±5.20* 
GROUP II  85.25±2.63 83.75±1.71 91.75±6.18 
GROUP III 84.50±1.29 85.25±1.71 91.75±4.19 
GROUP IV 85.75±2.75 85.75±1.26 86.50±3.70 
GROUP V 88.25±2.99 84.75±.50 92.25±5.91 
GROUP VI 86.75±3.77 85.25±2.22 88.50±4.51 
 VALUES ARE EXPRESSED AS MEAN ± SD, N=6, *= P<0.05 
 
GROUP I – ALLOXAN                                                         GROUP II – COMPOUND I WITH ALLOXAN 
GROUP III – COMPOUND II WITH ALLOXAN           GROUP IV – COMPOUND III WITH ALLOXAN 
GROUP V – COMPOUND IV WITH ALLOXAN              GROUP VI – GLIBENCLAMIDE WITH ALLOXAN 
SUMMARY AND CONCLUSION: 
• Twenty five molecules which passed Lipinski’s rule were docked against DPP-4. 
• The molecule containing purine and pyridine nucleus was selected on the basis of 
synthetic feasibility. 
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• Four compounds with top scores were synthesized, purified, characterized using 
UV, IR and NMR spectroscopy and Mass spectrometry. 
• These four compounds were subjected to acute toxicity studies to fix the LD50. The 
LD50 value of the title compounds (SR A- SR D) was expected to exceed 50mg/kg. 
• All the synthesised compound so were subjected to, invivo experiment to determine 
antidiabetic activity and were found to decrease the blood glucose levels, but they 
did not fare better than the standard drug glibenclamide. 
FUTURE: 
                      The synthesized compounds showed good anti-diabetic activity. Hence the 
anti-diabetic study deserves for further investigations like MTT Assay using different cell 
lines.   Based upon the literature, purine and pyridine have wide pharmacological activity, 
so the synthesized compounds deserves for further investigation against new therapeutic 
targets. 
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